The limited peripheral distribution reduces treatment-associated on-target off-tumor toxicity, and the preclinical study has demonstrated that the toxicity of KN046 is lower than that of the anti-CTLA-4 inhibitor. This evidence concerns the gene CTLA4 and neoplasm.